A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer.

Trial Profile

A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil - (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2016

At a glance

  • Drugs Capecitabine (Primary) ; Cyclophosphamide; Cyclophosphamide; Doxorubicin; Fluorouracil; Methotrexate
  • Indications Breast cancer; Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2011 Primary endpoint of QOL substudy identified as Hospital Anxiety and Depression Rating Scale as published in the Journal of Clinical Oncology.
    • 07 Feb 2011 Results published in the Journal of Clinical Oncology.
    • 20 Apr 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top